Resources

Despite some challenges due to the covid situation, the installation of the Cyclone®70 at AZ Isotopes in Indiana is progressing well! After a rigging in August, the commissioning is progressing well with beam extraction up to target position. Shortly the IBA Germanium and Iodine target/chemistry systems will be added on that machine to provide an effective oncology solution for US market. Congratulations to the whole team involved in this project! 

Louvain-La-Neuve, Belgium, 20 May 2021 - IBA (Ion Beam Applications S.A., EURONEXT), the world’s leading provider of proton therapy solutions for the treatment of cancer, today announces its business update for the first quarter ending 31 March 2021. Group Overview ▪ Strong balance sheet maintained, with EUR 152 million unaudited gross cash (31 Dec 2020: EUR 151.3 million) and EUR 72.6 million unaudited net cash (31 Dec 2020: EUR 65.2 million) ▪ Business operations have remained solid into the first quarter of 2021, albeit with some continuing impact from COVID-19 related installation delays in Proton Therapy alongside some Other Accelerator delays ▪ Continued focus on sustainable growth and profitability, delivering the very best offering and services to our customers, whilst remaining committed to corporate responsibility ▪ As part of a long-term employee incentive plan, IBA’s share buyback program was launched in January 2021 and is almost complete Olivier Legrain, Chief Executive Officer of IBA commented: “I have been pleased to see IBA’s continued resilience in the first quarter of 2021, with growing momentum in Proton Therapy in the US, continued success in Asia and strong performance in our Dosimetry and Other Accelerators businesses.” “Our roadmap to sustainable growth and profitability is clear: capitalize on our market leading position globally, invest for strategic impact and deliver operational execution. This focus will be reinforced by our continuing commitment to our customers, our employees and to the planet and I am proud of the groundwork we are laying as a company towards a true stakeholder approach to our business.”

Two IBA Rhodotron®TT 300-HE (High Energy) electron beam accelerators were rigged in Beloit, Wisconsin. The accelerators are critical components in a first-of-its-kind commercial-scale process to produce Mo-99, the parent radioisotope of technetium-99m, the most widely used medical imaging radioisotope, informing healthcare decisions for approximately 40,000 U.S. patients daily. We are proud to be part of this project !

Ever since IBA launched its first cyclotron in 1986, we have been on a mission to innovate and push the boundaries of technology further. Our goal? Offer you the best technology and services, while ensuring a high return on investment and low cost of ownership. We are pleased to invite you to a breakthrough announcement that’s a significant jump into the future. We’ll be holding an online event and will be honoured if you would attend.  When? June 10th 2021 at 3.00 pm CET  Register